Global infectious disease diagnosis has long been constrained by two fundamental gaps that limit timely, precise care across diverse healthcare settings.
1. Traditional lab-based PCR faces inherent access barriers
Gold-standard nucleic acid testing historically requires dedicated molecular laboratories, complex infrastructure, and certified technologists to perform multi-step manual workflows.
This high threshold keeps molecular testing largely centralized in tertiary hospitals and central reference laboratories. For outpatient clinics, community health centers, and remote primary care settings,
access to rapid molecular testing remains limited — often forcing clinicians to make treatment decisions without definitive pathogen data.
2. Limited test panels hinder accurate diagnosis and fuel antibiotic overuse
Respiratory, gastrointestinal, and reproductive tract infections often present with overlapping clinical symptoms, and may involve polymicrobial pathogens. Single-target or low-plex assays fail to capture
the full clinical picture, necessitating repeated sampling and delaying accurate diagnosis.
While lab-based multiplex assays exist, their complex workflows and long turnaround times make them unsuitable for immediate clinical decision-making at the point of care. Most critically, the inability
to rapidly distinguish between viral and bacterial pathogens drives widespread empirical antibiotic use, accelerating antimicrobial resistance (AMR) — one of today’s top global public health threats.
The Shift: Why Molecular POCT Is Reshaping Diagnostics
This is precisely why molecular point-of-care testing represents one of the fastest-growing segments in the global IVD market. By integrating sample preparation, nucleic acid amplification, and result
analysis into a closed, automated workflow, it directly addresses both gaps above:
Democratized Access (Solving the Infrastructure Gap)
No dedicated molecular laboratory or highly specialized molecular technologists required. Sample-to-result systems enable high-quality testing directly at the patient’s side, expanding diagnostic
capacity to underserved care settings.
Multiplex Detection Power (Solving the Clinical Gap)
Advanced panels can identify dozens of pathogens simultaneously in a single sample. This enables precise etiological identification in one run, supporting targeted therapy and robust antimicrobial
stewardship.
At Chenhui Medical, we are at the forefront of this transformation with a purpose-built dual-platform strategy:
Our Multi-Disc (model:CQ-0404) system delivers high-plex testing for severe infection diagnosis in hospital inpatient and ICU settings;
Our Flex-Disc (model:CH-0104) portable system enables rapid, flexible testing for outpatient and primary care.